Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 20 April, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 543904 | NSE: MANKIND

Fundamental Analysis of Mankind Pharma Ltd

Basic Stock Data

Last Updated: April 20, 2024, 1:00 am

Market Cap 93,567 Cr.
Current Price 2,337
High / Low2,420/1,241
Stock P/E56.7
Book Value 216
Dividend Yield0.00 %
ROCE20.7 %
ROE17.0 %
Face Value 1.00

Data Source:

Competitors of Mankind Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Industry Average0 Cr0000%0%0%0

Quarterly Result

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Operating Profit309420522374381539635603
OPM %19%20%23%19%20%23%26%26%
Other Income819693242575867
Profit before tax270365517326355526612576
Tax %20%18%19%24%21%22%23%15%
Net Profit217298420249281409473487
EPS in Rs5.437.4410.496.217.0110.2211.8012.16

Last Updated: April 10, 2024, 6:22 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: April 6, 2024, 1:51 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit7787051,2441,3721,8421,6982,159
OPM %20%18%26%25%25%21%24%
Other Income2096494154200163225
Profit before tax9416911,2651,4401,8711,5632,070
Tax %26%26%24%25%26%20%
Net Profit6945149581,0841,3891,2481,650
EPS in Rs17.3312.8323.9227.0734.6831.1641.19
Dividend Payout %0%0%32%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

YoY Net Profit Growth (%)-25.94%86.38%13.15%28.14%-10.15%
Change in YoY Net Profit Growth (%)0.00%112.32%-73.23%14.98%-38.29%


Compounded Sales Growth
10 Years:%
5 Years:16%
3 Years:19%
Compounded Profit Growth
10 Years:%
5 Years:12%
3 Years:9%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:%
Return on Equity
10 Years:%
5 Years:22%
3 Years:21%
Last Year:17%

Last Updated: April 17, 2024, 10:14 am

Balance Sheet

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital40404040404040
Other Liabilities6525968771,0451,7101,5831,883
Total Liabilities4,0093,8514,5315,8808,9399,37110,564
Fixed Assets5347789459872,9273,1423,531
Other Assets1,7511,1641,6552,3303,1002,6323,056
Total Assets4,0093,8514,5315,8808,9399,37110,564

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 5405379609838211,799
Cash from Investing Activity -516-306-396-1,127-1,360-1,041
Cash from Financing Activity 8-240-55989579-710
Net Cash Flow31-95-554048

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow418.00515.00-2.00-100.00-687.00-4.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days231332242322
Inventory Days120126124169183132
Days Payable115101113122133103
Cash Conversion Cycle273843727352
Working Capital Days954441496040
ROCE %22%36%33%30%21%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023
No. of Shareholders1,31,9181,34,7311,27,449

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
SBI Blue Chip Fund2,807,0551.38599.47
Axis ELSS Tax Saver Fund1,961,6331.23418.93
Axis Bluechip Fund1,212,6140.79258.97
ICICI Prudential Balanced Advantage Fund1,154,1410.45246.48
SBI Magnum Midcap Fund1,123,9091.46240.02
HDFC Top 100 Fund - Regular Plan1,044,5720.7223.08
Nippon India Pharma Fund900,7942.7192.37
ICICI Prudential Focused Equity Fund845,6912.5180.61
ICICI Prudential Value Discovery Fund845,5300.44180.57
ICICI Prudential Equity & Debt Fund800,6480.53170.99

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20
Basic EPS (Rs.)32.0035.7831.5925.72
Diluted EPS (Rs.)32.0035.7831.5925.72
Cash EPS (Rs.)40.5240.0734.9628.55
Book Value[Excl.RevalReserv]/Share (Rs.)190.30157.68121.3991.65
Book Value[Incl.RevalReserv]/Share (Rs.)190.30157.68121.3991.65
Revenue From Operations / Share (Rs.)218.41194.25155.13146.41
PBDIT / Share (Rs.)50.6654.5545.4138.62
PBIT / Share (Rs.)42.5250.3942.4436.15
PBT / Share (Rs.)41.4148.9341.9435.60
Net Profit / Share (Rs.)32.3835.9131.9926.08
NP After MI And SOA / Share (Rs.)32.0035.7831.5925.72
PBDIT Margin (%)23.1928.0829.2726.37
PBIT Margin (%)19.4625.9427.3524.69
PBT Margin (%)18.9525.1827.0324.31
Net Profit Margin (%)14.8218.4820.6117.81
NP After MI And SOA Margin (%)14.6518.4220.3617.56
Return on Networth / Equity (%)17.2423.2826.7929.56
Return on Capital Employeed (%)21.6930.9433.8737.96
Return On Assets (%)13.1915.6719.8520.31
Long Term Debt / Equity (X)
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.870.981.010.00
Current Ratio (X)2.321.682.892.24
Quick Ratio (X)1.521.012.011.53
Inventory Turnover Ratio (X)0.500.640.570.00
Dividend Payout Ratio (NP) (%)
Dividend Payout Ratio (CP) (%)
Earning Retention Ratio (%)
Cash Earning Retention Ratio (%)
Interest Coverage Ratio (X)45.6337.2990.2970.42
Interest Coverage Ratio (Post Tax) (X)30.1725.5464.6048.54
Retention Ratios (%)

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 2123.66

The stock is overvalued by 9.13% compared to the current price ₹2337

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness

  1. The stock has a high average ROCE of 23.67%, which is a positive sign.
  2. The company has higher reserves (5,308.86 cr) compared to borrowings (193.86 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (5.43 cr) and profit (234.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 54.83, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 50.83, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
    1. Net Profit Margin: 14.82%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 21.69% (Industry Average ROCE: 0%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 17.24% (Industry Average ROE: 0%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 30.17
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.52
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 56.7 (Industry average Stock P/E: 0)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.02
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating: ★★★★☆

About the Company

208, Okhla Industrial Estate, New Delhi Delhi 110020Mr.Ramesh%20Juneja
NamePosition Held
Mr. Rajeev JunejaVice Chairman & Mng.Director
Ms. Sheetal AroraWholeTime Director & CEO
Mr. Satish Kumar SharmaWhole Time Director
Mr. Vivek KalraIndependent Director
Mr. Tilokchand Punamchand OstwalIndependent Director
Mr. Surendra LuniaIndependent Director
Mr. Bharat AnandIndependent Director
Mr. Vijaya SampathIndependent Director

Mankind Pharma Ltd. Share Price Update

Share PriceValue
Previous Day₹2,397.40


What is the latest fair value of Mankind Pharma Ltd?

The latest fair value of Mankind Pharma Ltd is 2123.66.

What is the Market Cap of Mankind Pharma Ltd?

The Market Cap of Mankind Pharma Ltd is 93,567 Cr..

What is the current Stock Price of Mankind Pharma Ltd as on 20 April 2024?

The current stock price of Mankind Pharma Ltd as on 20 April 2024 is 2,337.

What is the High / Low of Mankind Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Mankind Pharma Ltd stocks is ₹2,420/1,241.

What is the Stock P/E of Mankind Pharma Ltd?

The Stock P/E of Mankind Pharma Ltd is 56.7.

What is the Book Value of Mankind Pharma Ltd?

The Book Value of Mankind Pharma Ltd is 216.

What is the Dividend Yield of Mankind Pharma Ltd?

The Dividend Yield of Mankind Pharma Ltd is 0.00 %.

What is the ROCE of Mankind Pharma Ltd?

The ROCE of Mankind Pharma Ltd is 20.7 %.

What is the ROE of Mankind Pharma Ltd?

The ROE of Mankind Pharma Ltd is 17.0 %.

What is the Face Value of Mankind Pharma Ltd?

The Face Value of Mankind Pharma Ltd is 1.00.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mankind Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE